Carter Thorne, MD, Discusses Biosimilar Switching in Canada

August 16, 2020


We sat down with Carter Thorne, MD, FRCPC, former president of the Canadian Rheumatology Association and chief of the Division of Rheumatology and director of The Arthritis Program at Southlake Regional Health Centre in Newmarket, Ontario, to discuss the current status of Canada’s comfort level with biosimilars and what he sees for the future of switching policies.

Sizing Up European Biosimilar Competition

August 9, 2020


We sat down with Adrian van den Hoven, director general of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, to discuss their scorecard report for biosimilar access and what European markets they feel need the most work.

Dorothy McCabe, PhD, Discusses How to Combat Biosimilar Misinformation

August 2, 2020


We sat down with Dorothy McCabe, PhD, the executive director of clinical development and medical affairs, immunology and biosimilars at Boehringer Ingelheim Pharmaceuticals and co-chair of the Biosimilars Forum education committee, to discuss what more needs to be done to combat biosimilar misinformation and how patients and physicians can help the cause.

Rathore: What Biosimilar Developers Can Learn From Application Failures

July 26, 2020


We sat down with Anurag Rathore, PhD, lead author of the study and coordinator of the Center of Excellence for Biopharmaceutical Technology in Delhi, India, to discuss the findings from this study and how biosimilar corporations can learn from them.

Byoungseo Choi on Celltrion's Biosimilar Goals For 2030

July 19, 2020


We sat down with Byoungseo Choi, the head of marketing for Celltrion Healthcare, to discuss exactly how this plan is going to work, the company’s current biosimilar pipeline, and its expectations for how their products will perform.

Ryan Haumschild, PharmD, Discusses Plan to Increase Biosimilar Utilization

July 12, 2020


We sat down with Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare, to discuss how this program has empowered biosimilar utilization within Emory and how Emory’s initiatives could be implemented on a larger scale.

Dr Jing Chao Discusses Knowledge Gaps and the Future for Biosimilar Insulins

July 5, 2020


We sat down with Jing Chao, MD, an assistant professor of medicine and metabolism, endocrinology and nutrition at the University of Washington in Seattle and one of the lead investigators of this study to discuss the findings of this study as well as how biosimilar insulins could pave the way for increased patient access.

Joe Fuhr, PhD, Discusses His Predictions for the Growing Biosimilar Market

June 28, 2020


We sat down with Joe Fuhr, PhD, professor emeritus of economics at Widener University in Chester, Pennsylvania, and an expert on antitrust health economics and pharmacoeconomics to discuss the current state of the biosimilar landscape and what he sees going forward.

Nick Mitrokostas Discusses New Biosimilar Approval and the Outlook for 2020

June 21, 2020


In this episode of Not So Different, we sat down with Nick Mitrokostas, an intellectual property (IP) lawyer and partner at Goodwin's IP Litigation group, to discuss how the approval of Pfizer’s pegfilgrastim biosimilar (Nyvepria) will affect the biosimilar market and what he sees for the rest of 2020.

Christine Simmon Discusses AAM Efforts for Biosimilar Legislation

June 14, 2020


We sat down with Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the AAM, to discuss some of the advocacy changes the organization is looking to advance and their chances of approval.